NEW YORK (GenomeWeb) – Interleukin Genetics on Monday announced that it would suspend its genetic testing program for severe gum disease and elevated systemic inflammation over the next 60 days after it was unable to defer a debt payment.

The Waltham, Massachusetts-based firm said it would also lay off five employees, or 63 percent of its current workforce. The decisions come as the company pursues strategic alternatives, Interleukin CEO Mark Carbeau said in a statement.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Dec
03
Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the National Institutes of Health evaluated a novel in situ hybridization approach and applied it to study splice variants related to schizophrenia.

Dec
04
Sponsored by
Sophia Genetics

This webinar will discuss the use of clinical-grade exome analysis application in complex case investigations.

Dec
12

This webinar will discuss the use of shotgun metagenomics to identify children at risk of hospital-acquired infection.